(HealthDay)—For patients with hematologic malignancies, septic shock is associated with high mortality rates and poor 90-day survival, according to a study published in the January issue of the Journal of the National Comprehensive ...
Jan 26, 2022
0
9
The first study to evaluate the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicates they remained at high risk for hospitalization and death.
Dec 24, 2021
0
248
Mount Sinai and UC San Diego researchers have shown for the first time how mutations affecting a cellular process called RNA splicing alter cells to develop myelodysplastic syndrome (MDS) and other hematologic malignancies ...
Oct 7, 2021
0
21
(HealthDay)—There is a familial risk for hematologic malignancies, according to a study published online June 16 in Cancers.
Jul 7, 2021
0
1
(HealthDay)—Fifty-five percent of children, adolescents, and young adults with hematologic malignancies experience high-intensity end-of-life care (HI-EOLC), with an increased likelihood for those treated at medium or large ...
Jul 6, 2021
0
1
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma ...
Apr 12, 2021
0
1
People with cancers of the blood, bone marrow or lymph nodes are at an increased risk of not making protective coronavirus antibodies after COVID-19 vaccination, a new study warns.
Apr 12, 2021
0
4
Higher viral loads are associated with a greater risk of death among cancer and non-cancer patients hospitalized with coronavirus disease 2019 (COVID-19), researchers report September 15 in the journal Cancer Cell. Among ...
Sep 16, 2020
0
4
Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply. A tyrosine ...
Jul 31, 2020
0
72
With improved treatments, especially the use of anti-cancer immunotherapies, more than two-thirds of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) will survive. However, after treatment, patients are at ...
Oct 8, 2019
0
2
